more episodes of recurrent C. difficile, cost-effectiveness results will favor fidaxomicin when this adverse impact is greater. As there are no formal studies on quality of life among patients with C. difficile infection, both investigators used estimates from chemotherapy-associated diarrhea [5, 6] . The values used in Stranges's model assumed more severe adverse quality-of-life effects compared with those used in Bartsch's model. In addition, Stranges and colleagues incorporated C. difficile-associated complications such as colectomy and mortality in calculating QALYs, whereas Bartsch and colleagues did not include these outcomes. Bartsch et al acknowledge that their estimates likely underestimate the severity of C. difficile-associated diarrhea, but they did not report sensitivity analyses on quality of life, symptom duration, or the number of recurrent episodes. Future work to better quantify C. difficile-associated impairments in quality of life will be critical in evaluating the cost-effectiveness of emerging C. difficile treatment strategies such as monoclonal antibodies and fecal microbiota transplant. 
